Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
83513-48-8
Molecular formula
Not available
Molecular weight
~5500 g/mol
Drug class
Low-molecular-weight heparinoidantithrombin-dependent anti-factor Xa anticoagulant
Mechanism of action
Enhances antithrombin-mediated inhibition of factor Xa and, to a lesser extent, thrombin. It has a low cross-reactivity with platelet factor 4 antibodies compared with heparin, making it an option in selected heparin-induced thrombocytopenia settings.
Indications / reported uses
Prevention and treatment of venous thromboembolism in patients with heparin-induced thrombocytopenia (HIT) or at risk of HIT in countries where danaparoid is authorised; use requires specialist anticoagulation monitoring
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Danaparoid PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Danaparoid Permitted Daily Exposure (PDE) report (the Danaparoid PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Danaparoid Occupational Exposure Limit (OEL) report (the Danaparoid OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.